Our GSK Oncology is back in full swing Axel Hoos on the Merck bispecific deal. Adding interview to NatalieGrover \'s story this morning. httpsendpts.comaftertesarobuygskwadesdeeperintocancerunveilingbigimmunotherapydealwithgerma

“Our GSK Oncology is back in full swing,” -- Axel Hoos on the Merck bispecific deal. Adding interview to @NatalieGrover 's story this morning. https://endpts.com/after-tesaro-buy-gsk-wades-deeper-into-cancer-unveiling-big-immunotherapy-deal-with-germa

09:19 EST 5 Feb 2019 | Brad Loncar

“Our GSK Oncology is back in full swing,” -- Axel Hoos on the Merck bispecific deal. Adding interview to @NatalieGrover 's story this morning. https://endpts.com/after-tesaro-buy-gsk-wades-deeper-into-cancer-unveiling-big-immunotherapy-deal-with-germanys-merck/ …

More From BioPortfolio on "“Our GSK Oncology is back in full swing,” -- Axel Hoos on the Merck bispecific deal. Adding interview to @NatalieGrover 's story this morning. https://endpts.com/after-tesaro-buy-gsk-wades-deeper-into-cancer-unveiling-big-immunotherapy-deal-with-germa"